SITC Archive Library

The Society for Immunotherapy of Cancer (SITC) hosted "Keynote - Richard Smalley, MD Memorial Lectureship" during the SITC 31st Annual Meeting & Associated Programs on November 11-13, 2016. Available here are the presentation slides and video from the keynote lectureship.

SITC 31st Annual Meeting Organizers 

• Chair: Lisa H. Butterfield, PhD – University of Pittsburgh 
• James L. Gulley, MD, PhD, FACP – National Cancer Institute, National Institutes of Health 
• Elizabeth A. Repasky, PhD – Roswell Park Cancer Institute 
• Laura S. Wood, RN, MSN, OCN – Cleveland Clinic Taussig Cancer Institute 
• Holbrook E. Kohrt, MD, PhD – Stanford Cancer Institute 
  
  

Program Summary

Dr. Topalian received her medical degree from the Tufts University School of Medicine and completed a general surgery residency at the Thomas Jefferson University Hospital in Philadelphia.  She was a research fellow and then a Senior Investigator in the National Cancer Institute, NIH.  She joined the Johns Hopkins faculty in 2006 to become the inaugural director of the Melanoma Program in the Kimmel Cancer Center.   Dr. Topalian is a physician-scientist whose studies of human anti-tumor immunity have provided a foundation for the clinical development of cancer vaccines, adoptive T cell transfer, and immune-modulating monoclonal antibodies.  Her current research focuses on manipulating “immune checkpoints” such as PD-1 in cancer therapy, and discovering biomarkers predicting clinical outcomes.  Dr. Topalian has received numerous awards for these contributions.  She was named one of Nature’s 10 in 2014, and received the Karnofsky Award from the American Society of Clinical Oncology in 2015.  Her work has opened new avenues of scientific investigation in cancer immunology and immunotherapy, and has established this treatment approach as a pillar of oncology.

Intended Audience

The target audience for this program included basic and clinical investigators from academic institutions, industry and regulatory agencies, including clinicians, researchers, graduate students, post-doctoral fellows, and allied health professionals involved in cancer research as well as pharmacists and payers that wished to learn more about cancer immunology and immunotherapy and its incorporation into current (and future) effective cancer treatment.

Disclaimer: Due to the rapidly-evolving field of cancer immunotherapy, some of the content on this page may be out of date. For current information from SITC on cancer immunotherapy, scroll down to view Related Entries and Links.

#Biomarkers#ClinicalTrials#ColonCancer#GenitourinaryCancers
#Melanoma#MerkelCellCarcinoma#NonSmallCellLungCancer
#PresentationSlides#Video#AnnualMeeting#SITC#AdverseEvents
#ImmuneCheckpointInhibitors#Nivolumab#Pembrolizumab#AlliedHealth
#Clinician#RegisteredNurse#Oncologist#Pharmacist#Researcher